ORGO Stock Analysis: Buy, Sell, or Hold?
ORGO - Organogenesis Holdings Inc. Class A Common Stock
$4.23
0.23 (5.75%)
▲
5d:
+7.09%
30d:
-18.34%
90d:
+0.0%
BUY
HIGH Confidence
Last Updated: February 2, 2026
Earnings: Feb 26, 2026
22d
Get Alerted When ORGO Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
✅ BUY SIGNAL: ORGO shows strong fundamentals and good volume confirmation. Solid entry point despite fair pricing.
✅ BUY SIGNAL: ORGO shows strong fundamentals and good volume confirmation. Solid entry point despite fair pricing.
In-depth Analysis How we analyze
Valuation Analysis: ORGO is currently trading at $4.23, which is considered fair relative to its 30-day fair value range of $3.79 to $4.72. The stock's valuation (Forward PE: 24.9) is in line with its historical norms (27.3). Remarkably, the market is currently pricing in an annual earnings decline of 3.0% over the next few years. This pessimistic expectation contrasts with the company's recent 22.2% earnings growth, suggesting potential undervaluation if the company simply maintains stability.
Technical Outlook: Technically, ORGO is showing sideways momentum. The price is approaching resistance at $4.29. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 5.8% recently.
Market Sentiment: ORGO has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $8.50 (+100.9%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, ORGO is showing sideways momentum. The price is approaching resistance at $4.29. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 5.8% recently.
Market Sentiment: ORGO has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $8.50 (+100.9%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
FAIR
Fair Price Range
$3.79 -
$4.72
Company Quality Score
58/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
90.4%
All Signals
- NEUTRAL: Price in fair range
- BULLISH: Options cheap (IV 0th percentile)
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+5.8%)
- BULLISH: Trading 100.9% below Wall St target ($8.50)
Fair Price Analysis
30-Day Fair Range
$3.79 -
$4.72
Current vs Fair Value
FAIR
Expected Move (7 Days)
±$0.59
(13.9%)
Support & Resistance Levels
Support Level
$3.60
Resistance Level
$4.29
Current Trend
Sideways
Fundamental Context
Forward P/E (Next Year Est.)
24.88
Wall Street Target
$8.50
(+100.9%)
Revenue Growth (YoY)
31.0%
Earnings Growth (YoY)
22.2%
Profit Margin
0.2%
Valuation Discount vs History
-3.0% cheaper
PE vs Historical
24.9 vs 27.3
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-3.0%
(market-implied from PE analysis)
1-Year Target
$4.10
(-3%)
2-Year Target
$3.98
(-6%)
3-Year Target
$3.86
(-9%)
3-Yr Target (if PE normalizes)
(PE: 25→27)
$4.24
(+0%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 24.9, Growth: -22.7%)
$3.08
(+-27%)
Base:
(SPY PE: 22.3, Growth: -22.7%)
$2.76
(-35%)
Bear:
(PE: 19.0, Growth: -22.7%)
$2.35
(-45%)
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 24.9 to 27.3
Stabilization Target:
$4.64
(+9.7%)
PE Expansion Potential:
+9.7%
Last updated: February 02, 2026 9:22 PM ET
Data refreshes hourly during market hours. Next update: 10:22 PM
Data refreshes hourly during market hours. Next update: 10:22 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ORGO showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences I… |
STRONG BUY
25 analysts |
$180 | 60 BUY |
|
ZTS
Zoetis Inc |
STRONG BUY
19 analysts |
$154 | 56 HOLD |
|
LNTH
Lantheus Holdings Inc |
STRONG BUY
13 analysts |
$83 | 57 HOLD |
|
BCRX
BioCryst Pharmaceuticals… |
STRONG BUY
12 analysts |
$22 | 55 HOLD |
|
HCM
HUTCHMED DRC |
STRONG BUY
14 analysts |
$21 | 54 HOLD |